Thromboxane in Pregnancy-Induced Hypertension.
- Author:
Kyu Chang LEE
1
;
Kyoung Min LEE
;
Chang Hoon LEE
;
So Joung KIM
;
Byoung Il YUN
;
Doo Yong CHUNG
Author Information
1. Department of Anesthesiology and Pain Medicine, College of Medicine, Konkuk University, Chung-Ju, Korea.
- Publication Type:Original Article
- Keywords:
Preeclampsia;
Thromboxane;
Enzyme immunoassay
- MeSH:
Aspirin;
Female;
Humans;
Hypertension, Pregnancy-Induced*;
Immunoenzyme Techniques;
Plasma;
Pre-Eclampsia;
Pregnancy;
Thromboxane A2
- From:Korean Journal of Obstetrics and Gynecology
2004;47(9):1680-1683
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: High thromboxane level evidence supports pivotal involvement of TxA2 in pathophysiology of pregnancy induced hypertension and provides a strong rationale for pursuing TxA2-blocking strategies in drug development. METHODS: The stable metabolites of TXA2 (Thromboxane B2) in maternal blood of 12 patients with mild preeclampsia, 4 patients with severe preeclampsia and 14 normal parturients were measured by competitive enzyme immunoassay. RESULTS: TxB2 concentrations were not increased in mild preeclampsia (101 +/- 12 pg/mL, n=12) as compared with normal pregnancy (150 +/- 15 pg/mL, n=14), but they were significantly increased in severe preeclampsia (454 +/- 102 pg/mL, p<0.0001, n=4). CONCLUSION: Maternal plasma thromboxane is increased only in severe preeclampsia. Thus, increased thromboxane A2 biosynthesis correlates with disease severity and may have a pathogenetic role in pregnancy-induced hypertension. These findings provide a rationale for the use of aspirin in the treatment as well as in the prevention of this disorder.
